Collectively, these observations indicated the possibility that PC patients who harbor mutated KRAS or TP53 might have shorter survival times if they simultaneously expressed high ANKRD22 compared to those who expressed lower ANKRD22, highlighting the crucial role of ANKRD22 in PC. Here, TP53 is linked to pachyonychia congenita.